NCT04167137 is a Phase 1 clinical trial of SYNB1891 in Metastatic Solid Neoplasm, sponsored by Synlogic.

Who is sponsoring NCT04167137?

NCT04167137 is sponsored by Synlogic.

What drugs are being tested in NCT04167137?

Interventions in NCT04167137: SYNB1891, Atezolizumab.

What condition does NCT04167137 study?

NCT04167137 studies Metastatic Solid Neoplasm, Lymphoma.

Is NCT04167137 still recruiting?

NCT04167137 is currently terminated. Last updated 3 May 2024.

Are results published for NCT04167137?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2024-05-03 · How we verify

NCT04167137

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants

Terminated Phase 1 Results posted Last updated 3 May 2024

What this trial tests

Phase 1 trial testing SYNB1891 in Metastatic Solid Neoplasm in 32 participants. Terminated before completion.

Timeline

12 December 2019

Primary endpoint
9 December 2021

9 December 2021

Quick facts

Lead sponsor	Synlogic
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	32
Start date	12 December 2019
Primary completion	9 December 2021
Estimated completion	9 December 2021
Sites	6 locations across United States

Drugs / interventions tested

SYNB1891 — full drug profile →
Atezolizumab (atezolizumab) — full drug profile →

Conditions studied

Metastatic Solid Neoplasm — all drugs for Metastatic Solid Neoplasm →
Lymphoma — all drugs for Lymphoma →

Sponsor

Synlogic — full company profile →

Who can join

18 and older, any sex, with Metastatic Solid Neoplasm or Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of Participants With Dose-limiting Toxicity Primary · 21 days (1 cycle)

The following adverse events (AEs) were DLTs if they occurred in Cycle 1 and were assessed by the Investigator as related to treatment: 1. Grade (Gr) 4 nonhematologic toxicity (not laboratory) 2. Gr 4 hematologic toxicity ≥ 7 days, any Gr 4 thrombocytopenia, or Gr 3 thrombocytopenia with significant bleeding 3. Gr ≥ 3 nonhematologic toxicity (exceptions: Gr 3 fatigue ≤ 3 days; Gr 3 diarrhea, nausea, or vomiting without treatment; Gr 3 rash without treatment) 4. Gr 3/4 nonhematologic laboratory value for \> 1 week or resulting in significant medical intervention, hospitalization, or drug-induc

Group	Value	95% CI
Arm 1 Cohort 1: SYNB1891 Monotherapy (1 × 10^6 Live Cells)	0
Arm 1 Cohort 2: SYNB1891 Monotherapy (3 × 10^6 Live Cells)	0
Arm 1 Cohort 3: SYNB1891 Monotherapy (1 × 10^7 Live Cells)	0
Arm 1 Cohort 4: SYNB1891 Monotherapy (3 × 10^7 Live Cells)	0
Arm 1 Cohort 5: SYNB1891 Monotherapy (1 × 10^8 Live Cells)	0
Arm 1 Cohort 6: SYNB1891 Monotherapy (3 × 10^8 Live Cells)	1
Arm 2 Cohort 1: SYNB1891 (1 × 10^7 Live Cells) + Atezolizumab	0
Arm 2 Cohort 2: SYNB1891 (3 × 10^7 Live Cells) + Atezolizumab	0

Number of Participants With Treatment-Emergent Adverse Events Secondary · Up to 13 months

Toxicity was graded in accordance with the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 5.0, as follows: Grade 1 (mild/asymptomatic; no intervention); Grade 2 (moderate; minimal intervention); Grade 3 (severe/medically significant; hospitalization indicated; disabling); Grade 4 (life-threatening; urgent intervention required); or Grade 5 (fatal). Adverse events (AEs) were reported from clinical laboratory tests, vital sign and weight measurements, physical examinations, and any other medically indicated assessments, including participant inter

Any TEAE

Group	Value	95% CI
Arm 1 Cohort 1: SYNB1891 Monotherapy (1 × 10^6 Live Cells)	3
Arm 1 Cohort 2: SYNB1891 Monotherapy (3 × 10^6 Live Cells)	3
Arm 1 Cohort 3: SYNB1891 Monotherapy (1 × 10^7 Live Cells)	4
Arm 1 Cohort 4: SYNB1891 Monotherapy (3 × 10^7 Live Cells)	5
Arm 1 Cohort 5: SYNB1891 Monotherapy (1 × 10^8 Live Cells)	3
Arm 1 Cohort 6: SYNB1891 Monotherapy (3 × 10^8 Live Cells)	6
Arm 2 Cohort 1: SYNB1891 (1 × 10^7 Live Cells) + Atezolizumab	4
Arm 2 Cohort 2: SYNB1891 (3 × 10^7 Live Cells) + Atezolizumab	4

Maximum TEAE severity Grade 1

Group	Value	95% CI
Arm 1 Cohort 1: SYNB1891 Monotherapy (1 × 10^6 Live Cells)	0
Arm 1 Cohort 2: SYNB1891 Monotherapy (3 × 10^6 Live Cells)	1
Arm 1 Cohort 3: SYNB1891 Monotherapy (1 × 10^7 Live Cells)	2
Arm 1 Cohort 4: SYNB1891 Monotherapy (3 × 10^7 Live Cells)	1
Arm 1 Cohort 5: SYNB1891 Monotherapy (1 × 10^8 Live Cells)	1
Arm 1 Cohort 6: SYNB1891 Monotherapy (3 × 10^8 Live Cells)	0
Arm 2 Cohort 1: SYNB1891 (1 × 10^7 Live Cells) + Atezolizumab	1
Arm 2 Cohort 2: SYNB1891 (3 × 10^7 Live Cells) + Atezolizumab	1

Maximum TEAE severity Grade 2

Group	Value	95% CI
Arm 1 Cohort 1: SYNB1891 Monotherapy (1 × 10^6 Live Cells)	1
Arm 1 Cohort 2: SYNB1891 Monotherapy (3 × 10^6 Live Cells)	1
Arm 1 Cohort 3: SYNB1891 Monotherapy (1 × 10^7 Live Cells)	1
Arm 1 Cohort 4: SYNB1891 Monotherapy (3 × 10^7 Live Cells)	1
Arm 1 Cohort 5: SYNB1891 Monotherapy (1 × 10^8 Live Cells)	1
Arm 1 Cohort 6: SYNB1891 Monotherapy (3 × 10^8 Live Cells)	3
Arm 2 Cohort 1: SYNB1891 (1 × 10^7 Live Cells) + Atezolizumab	3
Arm 2 Cohort 2: SYNB1891 (3 × 10^7 Live Cells) + Atezolizumab	1

Maximum TEAE severity Grade 3

Group	Value	95% CI
Arm 1 Cohort 1: SYNB1891 Monotherapy (1 × 10^6 Live Cells)	1
Arm 1 Cohort 2: SYNB1891 Monotherapy (3 × 10^6 Live Cells)	0
Arm 1 Cohort 3: SYNB1891 Monotherapy (1 × 10^7 Live Cells)	1
Arm 1 Cohort 4: SYNB1891 Monotherapy (3 × 10^7 Live Cells)	3
Arm 1 Cohort 5: SYNB1891 Monotherapy (1 × 10^8 Live Cells)	1
Arm 1 Cohort 6: SYNB1891 Monotherapy (3 × 10^8 Live Cells)	3
Arm 2 Cohort 1: SYNB1891 (1 × 10^7 Live Cells) + Atezolizumab	0
Arm 2 Cohort 2: SYNB1891 (3 × 10^7 Live Cells) + Atezolizumab	1

Maximum TEAE severity Grade 4

Group	Value	95% CI
Arm 1 Cohort 1: SYNB1891 Monotherapy (1 × 10^6 Live Cells)	0
Arm 1 Cohort 2: SYNB1891 Monotherapy (3 × 10^6 Live Cells)	0
Arm 1 Cohort 3: SYNB1891 Monotherapy (1 × 10^7 Live Cells)	0
Arm 1 Cohort 4: SYNB1891 Monotherapy (3 × 10^7 Live Cells)	0
Arm 1 Cohort 5: SYNB1891 Monotherapy (1 × 10^8 Live Cells)	0
Arm 1 Cohort 6: SYNB1891 Monotherapy (3 × 10^8 Live Cells)	0
Arm 2 Cohort 1: SYNB1891 (1 × 10^7 Live Cells) + Atezolizumab	0
Arm 2 Cohort 2: SYNB1891 (3 × 10^7 Live Cells) + Atezolizumab	0

Maximum TEAE severity Grade 5

Group	Value	95% CI
Arm 1 Cohort 1: SYNB1891 Monotherapy (1 × 10^6 Live Cells)	1
Arm 1 Cohort 2: SYNB1891 Monotherapy (3 × 10^6 Live Cells)	1
Arm 1 Cohort 3: SYNB1891 Monotherapy (1 × 10^7 Live Cells)	0
Arm 1 Cohort 4: SYNB1891 Monotherapy (3 × 10^7 Live Cells)	0
Arm 1 Cohort 5: SYNB1891 Monotherapy (1 × 10^8 Live Cells)	0
Arm 1 Cohort 6: SYNB1891 Monotherapy (3 × 10^8 Live Cells)	0
Arm 2 Cohort 1: SYNB1891 (1 × 10^7 Live Cells) + Atezolizumab	0
Arm 2 Cohort 2: SYNB1891 (3 × 10^7 Live Cells) + Atezolizumab	1

TEAE related to SYNB1891

Group	Value	95% CI
Arm 1 Cohort 1: SYNB1891 Monotherapy (1 × 10^6 Live Cells)	3
Arm 1 Cohort 2: SYNB1891 Monotherapy (3 × 10^6 Live Cells)	1
Arm 1 Cohort 3: SYNB1891 Monotherapy (1 × 10^7 Live Cells)	2
Arm 1 Cohort 4: SYNB1891 Monotherapy (3 × 10^7 Live Cells)	3
Arm 1 Cohort 5: SYNB1891 Monotherapy (1 × 10^8 Live Cells)	3
Arm 1 Cohort 6: SYNB1891 Monotherapy (3 × 10^8 Live Cells)	6
Arm 2 Cohort 1: SYNB1891 (1 × 10^7 Live Cells) + Atezolizumab	2
Arm 2 Cohort 2: SYNB1891 (3 × 10^7 Live Cells) + Atezolizumab	2

TEAE related to atezolizumab

Group	Value	95% CI
Arm 1 Cohort 1: SYNB1891 Monotherapy (1 × 10^6 Live Cells)	0
Arm 1 Cohort 2: SYNB1891 Monotherapy (3 × 10^6 Live Cells)	0
Arm 1 Cohort 3: SYNB1891 Monotherapy (1 × 10^7 Live Cells)	0
Arm 1 Cohort 4: SYNB1891 Monotherapy (3 × 10^7 Live Cells)	0
Arm 1 Cohort 5: SYNB1891 Monotherapy (1 × 10^8 Live Cells)	0
Arm 1 Cohort 6: SYNB1891 Monotherapy (3 × 10^8 Live Cells)	0
Arm 2 Cohort 1: SYNB1891 (1 × 10^7 Live Cells) + Atezolizumab	0
Arm 2 Cohort 2: SYNB1891 (3 × 10^7 Live Cells) + Atezolizumab	2

Number of Participants With Best Tumor Response as Measured by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) Secondary · Up to 13 months

Appropriate imaging of the SYNB1891-injected tumor(s) and up to 5 target (noninjected) lesions was performed at baseline and every 2 cycles during the treatment period. Tumor response was assessed by the local investigator using RECIST 1.1 (Eisenhauer et al 2009). Per RECIST 1.1, target lesions are categorized as follows: complete response (CR): disappearance of all target lesions (no evaluable disease); partial response (PR): ≥ 30% decrease in the sum of the longest diameter of target lesions; progressive disease (PD): ≥ 20% increase in the sum of the longest diameter of target lesions; stabl

Group	Value	95% CI
Arm 1 Cohort 1: SYNB1891 Monotherapy (1 × 10^6 Live Cells)	1
Arm 1 Cohort 2: SYNB1891 Monotherapy (3 × 10^6 Live Cells)	1
Arm 1 Cohort 3: SYNB1891 Monotherapy (1 × 10^7 Live Cells)	1
Arm 1 Cohort 4: SYNB1891 Monotherapy (3 × 10^7 Live Cells)	1
Arm 1 Cohort 5: SYNB1891 Monotherapy (1 × 10^8 Live Cells)	1
Arm 1 Cohort 6: SYNB1891 Monotherapy (3 × 10^8 Live Cells)	1
Arm 2 Cohort 1: SYNB1891 (1 × 10^7 Live Cells) + Atezolizumab	1
Arm 2 Cohort 2: SYNB1891 (3 × 10^7 Live Cells) + Atezolizumab	2
Arm 1 Cohort 1: SYNB1891 Monotherapy (1 × 10^6 Live Cells)	1
Arm 1 Cohort 2: SYNB1891 Monotherapy (3 × 10^6 Live Cells)	1
Arm 1 Cohort 3: SYNB1891 Monotherapy (1 × 10^7 Live Cells)	3
Arm 1 Cohort 4: SYNB1891 Monotherapy (3 × 10^7 Live Cells)	3
Arm 1 Cohort 5: SYNB1891 Monotherapy (1 × 10^8 Live Cells)	2
Arm 1 Cohort 6: SYNB1891 Monotherapy (3 × 10^8 Live Cells)	2
Arm 2 Cohort 1: SYNB1891 (1 × 10^7 Live Cells) + Atezolizumab	3
Arm 2 Cohort 2: SYNB1891 (3 × 10^7 Live Cells) + Atezolizumab	1

Adverse events — posted to ClinicalTrials.gov

Time frame: All AEs occurring from the time a participant signed informed consent through the safety follow-up period were documented, regardless of the causal relationship to study drug. AEs that occurred or worsened in severity after the first dose of study treatment were considered treatment emergent (i.e., TEAEs). The longest duration of study participation for any participant was 13 months.. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Arm 1 Cohort 1: SYNB1891 Monotherapy (1 × 10^6 Live Cells)

Serious: 1/3 (33%)

Deaths: 2/3

Arm 1 Cohort 2: SYNB1891 Monotherapy (3 × 10^6 Live Cells)

Serious: 1/3 (33%)

Deaths: 2/3

Arm 1 Cohort 3: SYNB1891 Monotherapy (1 × 10^7 Live Cells)

Serious: 1/4 (25%)

Deaths: 0/4

Arm 1 Cohort 4: SYNB1891 Monotherapy (3 × 10^7 Live Cells)

Serious: 3/5 (60%)

Deaths: 1/5

Arm 1 Cohort 5: SYNB1891 Monotherapy (1 × 10^8 Live Cells)

Serious: 0/3 (0%)

Deaths: 0/3

Arm 1 Cohort 6: SYNB1891 Monotherapy (3 × 10^8 Live Cells)

Serious: 3/6 (50%)

Deaths: 0/6

Arm 2 Cohort 1: SYNB1891 (1 × 10^7 Live Cells) + Atezolizumab

Serious: 0/4 (0%)

Deaths: 0/4

Arm 2 Cohort 2: SYNB1891 (3 × 10^7 Live Cells) + Atezolizumab

Serious: 2/4 (50%)

Deaths: 1/4

Serious adverse events (14 terms)

Reaction	System	Arm 1 Cohort 1: SYNB1891 M…	Arm 1 Cohort 2: SYNB1891 M…	Arm 1 Cohort 3: SYNB1891 M…	Arm 1 Cohort 4: SYNB1891 M…	Arm 1 Cohort 5: SYNB1891 M…	Arm 1 Cohort 6: SYNB1891 M…	Arm 2 Cohort 1: SYNB1891 (…	Arm 2 Cohort 2: SYNB1891 (…
Cytokine release syndrome	Immune system disorders	—	—	—	—	—	—	—	—
Aspiration	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—
Constipation	Gastrointestinal disorders	—	—	—	—	—	—	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—
Hypoxia	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—
Pulmonary embolism	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—
Sepsis	Infections and infestations	—	—	—	—	—	—	—	—
Syncope	Nervous system disorders	—	—	—	—	—	—	—	—
Synovial sarcoma metastatic	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—	—	—	—	—	—
Tracheal haemorrhage	Injury, poisoning and procedural complications	—	—	—	—	—	—	—	—
Transient ischaemic attack	Nervous system disorders	—	—	—	—	—	—	—	—
Tumour haemorrhage	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—	—	—	—	—	—
Vaginal haemorrhage	Reproductive system and breast disorders	—	—	—	—	—	—	—	—

Other adverse events (95 terms — click to expand)

Reaction	System	Arm 1 Cohort 1: SYNB1891 M…	Arm 1 Cohort 2: SYNB1891 M…	Arm 1 Cohort 3: SYNB1891 M…	Arm 1 Cohort 4: SYNB1891 M…	Arm 1 Cohort 5: SYNB1891 M…	Arm 1 Cohort 6: SYNB1891 M…	Arm 2 Cohort 1: SYNB1891 (…	Arm 2 Cohort 2: SYNB1891 (…
Chills	General disorders	—	—	—	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—	—	—	—
Hyponatraemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—
Tumour Pain	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—	—	—	—	—	—
Pyrexia	General disorders	—	—	—	—	—	—	—	—
Fatigue	General disorders	—	—	—	—	—	—	—	—
Decreased appetite	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—
Injection site pain	General disorders	—	—	—	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—	—	—	—
Anxiety	Psychiatric disorders	—	—	—	—	—	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—
Headache	Nervous system disorders	—	—	—	—	—	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—
Constipation	Gastrointestinal disorders	—	—	—	—	—	—	—	—
Injection site reaction	General disorders	—	—	—	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—	—	—	—
Hyperglycaemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—
Hypokalaemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—
Activated Partial Thromboplastin Time Prolonged	Investigations	—	—	—	—	—	—	—	—
Aspartate Aminotransferase Increased	Investigations	—	—	—	—	—	—	—	—
Blood Lactate Dehydrogenase Increased	Investigations	—	—	—	—	—	—	—	—
International Normalised Ratio Increased	Investigations	—	—	—	—	—	—	—	—
Corona Virus Infection	Infections and infestations	—	—	—	—	—	—	—	—
Urinary Tract Infection	Infections and infestations	—	—	—	—	—	—	—	—
Hypertension	Vascular disorders	—	—	—	—	—	—	—	—
Hypotension	Vascular disorders	—	—	—	—	—	—	—	—
Peripheral Swelling	General disorders	—	—	—	—	—	—	—	—
Abdominal Pain	Gastrointestinal disorders	—	—	—	—	—	—	—	—
Dysphagia	Gastrointestinal disorders	—	—	—	—	—	—	—	—
Blood Uric Acid Increased	Investigations	—	—	—	—	—	—	—	—
Lymphocyte Count Decreased	Investigations	—	—	—	—	—	—	—	—
Arthralgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—
Bursitis	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—
Groin pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—
Musculoskeletal pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—
Leukocytosis	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—
Conjunctivitis	Infections and infestations	—	—	—	—	—	—	—	—
Pneumonia	Infections and infestations	—	—	—	—	—	—	—	—
Epistaxis	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—
Productive Cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—

Most-reported serious reactions: Cytokine release syndrome, Aspiration, Back pain, Constipation, Dyspnoea, Hypoxia, Pulmonary embolism, Sepsis.

Data from ClinicalTrials.gov NCT04167137 adverse events section.

Sponsor's own description

This Phase 1, open-label, multicenter, 2-arm study was designed to evaluate SYNB1891 when administered either as monotherapy (Arm 1) or in combination with atezolizumab (Arm 2) in participants with advanced/metastatic solid tumors or lymphoma. The primary objective was to evaluate the safety and tolerability of study treatment, with a secondary objective of assessing preliminary tumor response to treatment and exploratory objectives of evaluating the pharmacokinetics/pharmacodynamics (PK/PD) of study treatment.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

The microbiome and human cancer.
Sepich-Poore GD, Zitvogel L, Straussman R, Hasty J, et al · · 2021 · cited 945× · PMID 33766858 · DOI 10.1126/science.abc4552
Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies.
Lu Y, Yuan X, Wang M, He Z, et al · · 2022 · cited 360× · PMID 35488243 · DOI 10.1186/s13045-022-01273-9
Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity.
Leventhal DS, Sokolovska A, Li N, Plescia C, et al · · 2020 · cited 326× · PMID 32483165 · DOI 10.1038/s41467-020-16602-0
STING Agonists as Cancer Therapeutics.
Amouzegar A, Chelvanambi M, Filderman JN, Storkus WJ, et al · · 2021 · cited 311× · PMID 34070756 · DOI 10.3390/cancers13112695
Engineering bacteria as interactive cancer therapies.
Gurbatri CR, Arpaia N, Danino T. · · 2022 · cited 288× · PMID 36423303 · DOI 10.1126/science.add9667
Targeting cytokine and chemokine signaling pathways for cancer therapy.
Yi M, Li T, Niu M, Zhang H, et al · · 2024 · cited 264× · PMID 39034318 · DOI 10.1038/s41392-024-01868-3
Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy.
Garland KM, Sheehy TL, Wilson JT. · · 2022 · cited 250× · PMID 35107989 · DOI 10.1021/acs.chemrev.1c00750
Type I interferon-mediated tumor immunity and its role in immunotherapy.
Yu R, Zhu B, Chen D. · · 2022 · cited 229× · PMID 35292881 · DOI 10.1007/s00018-022-04219-z

Verify or expand the search:

Other Synlogic trials

Trials by the same sponsor.

NCT05764239 — Efficacy and Safety of SYNB1934 in Patients With PKU (SYNPHENY-3) · Phase 3 · terminated
NCT05462132 — Safety, Tolerability and Pharmacodynamics of SYNB1353 in Healthy Adult Volunteers · Phase 1 · completed
NCT05377112 — Safety, Tolerability, and Pharmacodynamics of SYNB8802v1 in Subjects With History of Gastric Bypass Surgery or Short-bow · EARLY_PHASE1 · completed
NCT04984525 — Safety and Tolerability of SYNB1934 in Healthy Adult Volunteers · Phase 1 · completed
NCT04629170 — Safety and Tolerability of SYNB8802 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04167137 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Synlogic
Last refreshed: 3 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04167137.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing